Haibo Yu

Beijing Chao-yang Hospital

H指数:20

被引数:1,414

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting

新诊断急性髓系白血病中新兴的维奈克拉联合去甲基化药物为基础的三联方案：2025年ASH年会更新

Experimental Hematology & Oncology

IF13.5

2026-07-270

Efficacy differences of biologic agents targeting different pathways in obese patients with psoriasis: a systematic review and meta-analysis

肥胖银屑病患者中针对不同通路生物制剂的疗效差异：一项系统评价和荟萃分析

Journal of Dermatological Treatment

IF3.9

2026-01-010

Analgesic effect of cinobufagin is mediated by human-selective P2X7R antagonism governed by distinct extracellular domains

蟾蜍灵的镇痛效应是通过人源选择性P2X7R拮抗作用介导的，该拮抗作用受不同细胞外结构域调控。

Neuropharmacology

IF4.6

2025-11-300

PRE

SQOR as a metabolic rheostat of H2S: structure; redox homeostasis; and disease therapy

SQOR作为H2S的代谢调速器：结构；氧化还原稳态；以及疾病治疗

Frontiers in Cell and Developmental Biology

IF4.3

2025-10-230

OAAI

Grifolic acid, a FFAR4 agonist, identified as a dual antagonist of voltage-gated sodium and CaV2.2 channels with potent antinociceptive effects

Grifolic acid，一种FFAR4激动剂，被鉴定为电压门控钠离子和CaV2.2通道的双重拮抗剂，具有强大的镇痛作用。

British Journal of Pharmacology

IF7.7

2025-08-060

PRE

Discovery of novel 4-azaindole derivatives as selective Nav1.2 Inhibitor with potent antiepileptic activity and low neurotoxicity

新型4-氮杂吲哚衍生物作为选择性Nav1.2抑制剂的发现，具有强效的抗癫痫活性和低神经毒性。

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2025-05-100

PRE

Design, synthesis and structure-activity relationship of novel 1,2,4-triazolopyrimidin-5-one derivatives targeting GABAA1 and Nav1.2 with antiepileptic activity

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2025-03-010

PRE

Cerebellum abnormalities in vascular mild cognitive impairment with depression symptom patients: A multimodal magnetic resonance imaging study

BRAIN RESEARCH BULLETIN

IF3.7

2025-02-011

OAAI

Full biosynthetic pathway of pyrrolobenzoxazines

吡咯并苯并恶嗪的完整生物合成途径

CHINESE CHEMICAL LETTERS

IF8.9

2025-01-011

PRE

Disruptive and complementary effects of depression symptoms on spontaneous brain activity in the subcortical vascular mild cognitive impairment

FRONTIERS IN AGING NEUROSCIENCE

IF4.5

2024-09-170

OAAI

Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2024-07-090

PRE

Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca 2+ /CaMKII pathway ( vol 14 ,pg 435 , 2024)

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2024-06-010

OAAI

Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca 2+/CaMKII pathway

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2024-03-012

OAAI

Structural diversification of phenylspirodrimane lactams by employing a biosynthetic intermediate

CHINESE CHEMICAL LETTERS

IF8.9

2023-12-010

PRE

Schisandrin B, a dual positive allosteric modulator of GABAA and glycine receptors, alleviates seizures in multiple mouse models

ACTA PHARMACOLOGICA SINICA

IF8.4

2023-11-282

PRE

Construction of a virtual reality platform for computer-aided navigation Lingnan bone setting technique

BIOENGINEERED

IF4.2

2023-06-280

OAAI

NAN-190, a 5-HT1A antagonist, alleviates inflammatory pain by targeting Nav1.7 sodium channels

LIFE SCIENCES

IF5.1

2023-04-013

PRE

Rhodojaponin VI indirectly targets Cav2.2 channels via N-ethylmaleimide-sensitive fusion protein to alleviate neuropathic pain

ACTA PHARMACEUTICA SINICA B

IF14.6

2023-03-0111

OAAI

Antinociceptive activity of doliroside B

PHARMACEUTICAL BIOLOGY

IF4.8

2023-01-107

OAAI

Voltage-dependent potassium channel Kv4.2 alleviates the ischemic stroke impairments through activating neurogenesis

NEUROCHEMISTRY INTERNATIONAL

IF4

2021-11-016

PRE

Haibo Yu

个人简介

教育背景

工作经历

荣誉奖项

研究方向